

In re Application of: Britta HARDY et al.  
Serial No.: 10/577,679  
Filed: April 28, 2006  
Office Action Mailing Date: July 12, 2007

Examiner: NIEBAUER, Ronald T.  
Group Art Unit: 1654  
Attorney Docket: 31831

**In the Claims:**

1-35. (Canceled)

36. (Currently Amended) An isolated peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:6 and or 10, the peptide being no more than 50 amino acids in length.

37. (Currently Amended) An isolated peptide consisting of an amino acid sequence as set forth by selected from the group consisting of SEQ ID NOs:6 and or 10.

38. (Currently Amended) The isolated A-cyclic peptide of claim 36, wherein the peptide is a cyclic peptide, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 6, 10 and 12, the peptide being no more than 50 amino acid residues in length.

39-43. (Canceled)

44. (Currently Amended) A composition-of-matter comprising at least two peptides, each independently consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10 and 12.

45. (Canceled)

46. (Currently Amended) A pharmaceutical composition comprising as an active ingredient a peptide having comprising an amino acid sequence as set forth by selected from the group consisting of SEQ ID NOs:2, 6, 10 and or 12, said peptide

In re Application of: Britta HARDY et al.  
Serial No.: 10/577,679  
Filed: April 28, 2006  
Office Action Mailing Date: July 12, 2007

Examiner: NIEBAUER, Ronald T.  
Group Art Unit: 1654  
Attorney Docket: 31831

being no more than 50 amino acid residues in length and a pharmaceutically acceptable carrier or diluent.

47-52. (Canceled)

53. (Currently Amended) A composition for targeting a drug to endothelial cells, the composition comprising the drug fused to the isolated peptide of claim 37.

54-55. (Canceled)

56. (Currently Amended) The isolated peptide of claim 37, wherein the peptide is a linear peptide.

57. (Canceled)

58. (Currently Amended) The pharmaceutical composition of claim 46, wherein the isolated peptide is a linear peptide.

59. (Canceled)

60. (Currently Amended) The isolated peptide of claim 37, wherein the peptide is a cyclic peptide.

61. (Canceled)

62. (Previously Presented) The pharmaceutical composition of claim 46, wherein the peptide is a cyclic peptide.

In re Application of: Britta HARDY et al.  
Serial No.: 10/577,679  
Filed: April 28, 2006  
Office Action Mailing Date: July 12, 2007

Examiner: NIEBAUER, Ronald T.  
Group Art Unit: 1654  
Attorney Docket: 31831

63-69. (Canceled)

70. (New) A composition-of-matter comprising at least two peptides, each independently consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs:2, 4, 6, 8 and 10.

In re Application of: Britta HARDY et al.  
Serial No.: 10/577,679  
Filed: April 28, 2006  
Office Action Mailing Date: July 12, 2007

Examiner: NIEBAUER, Ronald T.  
Group Art Unit: 1654  
Attorney Docket: 31831

**In the Drawing:**

**Please amend line 6 in Figure 22b as follows:**

http://dna.stanford.edu/emotif/emotif-scan.html Hypertext Transfer

Protocol://dnadotstanforddottedu/emotif/emotif-scandorhtml

Amended Figure 22b is attached herewith (as an annotated marked up drawing sheet) together with a replacement drawing sheet.